Obesity Clinical Trial
Official title:
Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers in Class II and III Obesity
The study team's research fills the gap in the obesity literature where BMI with a cut point of 35 is frequently used to show the association between BMI and metabolic syndrome biomarkers. The study team was unable to locate any papers that showed the association between metabolic syndrome biomarkers and BMI from 35 to 69.9, and especially graphically as this clinical team has presented.
A positive association between BMI and metabolic health risk is often presented graphically
as a J-shaped curve with BMI on the x-axis and the biomarker of interest on the y-axis.
However, BMI is frequently presented in the literature with a cut point of 35 on the x-axis,
leading to the assumption that the steep association continues beyond a BMI of 35. This
presentation does not capture the metabolically healthy individual with obesity.
In the population of men and women with class II and II obesity who the clinical team
studied, it was examined that the association between BMI as a continuous variable from 35
to 69.9 and metabolic syndrome biomarkers (total-, low density, and high density
cholesterol, triglycerides, systolic and diastolic blood pressure, fasting blood glucose,
and glycosylated hemoglobin), the study team found no evidence for a positive correlation
between BMI and TC, LDL-C, TG, and FBG. And while the study team did find positive and
significant correlations between BMI and HDL-C, SBP, DBP, and HgbA1C, the effect sizes were
small and arguably clinically insignificant.
The study team's research fills the gap in the obesity literature where BMI with a cut point
of 35 is frequently used to show the association between BMI and metabolic syndrome
biomarkers. The clinical team was unable to locate any papers that showed the association
between metabolic syndrome biomarkers and BMI from 35 to 69.9, and especially graphically as
this clinical team has presented.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Recruiting |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Recruiting |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT03714646 -
Beta Glucan and Acetate Production
|
N/A | |
| Recruiting |
NCT03255005 -
Endomina Controlled Study
|
N/A | |
| Enrolling by invitation |
NCT03063606 -
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
|
Phase 2/Phase 3 | |
| Completed |
NCT03317587 -
Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)
|
N/A | |
| Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
| Active, not recruiting |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
| Completed |
NCT02235961 -
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
|
Phase 1 | |
| Completed |
NCT00341406 -
Fat Cell Size in Insulin Resistance
|
||
| Not yet recruiting |
NCT03470272 -
Effects of Red Light LED Therapy on Body Contouring
|
N/A | |
| Recruiting |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
| Recruiting |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
| Active, not recruiting |
NCT02918279 -
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
|
Phase 3 | |
| Completed |
NCT00494767 -
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
|
Phase 1 | |
| Recruiting |
NCT03338296 -
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
|
Phase 4 | |
| Recruiting |
NCT03672903 -
Effect of Different Weight Vests on Body Weight in Obese Individuals
|
Phase 1/Phase 2 |
